Anti-Human CD105 (Endoglin) APC
Catalog Number : 17111-80
description
The SN6 monoclonal antibody specifically reacts with human CD105 (Endoglin), a 90kDA homodimeric glycoprotein expressed on vascular endothelial cells, activated macrophages, and a subset of bone marrow cells. CD105 is a marker for tumor angiogenesis research by identifying proliferating endothelium. It is also suggested to be involved in embryonic angiogenesis and cellular adhesion.
Additional Information
|
Clone:
|
SN6
|
|
Format:
|
APC
|
|
Applications:
|
FC
|
|
Reactivity:
|
Human
|
|
Isotype:
|
IgG1, kappa
|
| Research Interest: | Stem Cell Research, Angiogenesis |
|---|---|
| Cell Type: | Macrophage / Monocyte, Stem Cells |
| Application: | FC |
| Clone: | SN6 |
|
Preparation:
|
The product should be stored undiluted at 4°C and should be protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.
|
|
Formulation:
|
Aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer.
|
|
References:
|
Pierelli, L., Bonanno, G., Rutella, S., Marone, M., Scambia, G., & Leone, G. (2001). CD105 (endoglin) expression on hematopoietic stem/progenitor cells.Leukemia & lymphoma, 42(6), 1195-1206. She, X., Matsuno, F., Harada, N., Tsai, H., & Seon, B. K. (2004). Synergy between anti‐endoglin (CD105) monoclonal antibodies and TGF‐beta; in suppression of growth of human endothelial cells. International journal of cancer, 108(2), 251-257. Seon, B. K., & Kumar, S. (2002). CD105 antibody for targeting of tumor vascular endothelial cells. In The new angiotherapy (pp. 499-515). Humana Press. |